Simplify Logo

Full-Time

Quality Assurance Specialist

Supplier Quality

Updated on 10/21/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$123k - $134kAnnually

+ Equity Component + Comprehensive Benefits

Mid

San Carlos, CA, USA

Hybrid position.

Category
QA & Testing
Quality Assurance
Requirements
  • Bachelor’s degree in Chemistry, Biology, Pharmacy, Engineering, or a related field.
  • Minimum of 3-5 years of experience in quality assurance, supplier quality, or quality systems management within the pharmaceutical, biotechnology, or life sciences industry.
  • Knowledge of cGMP, ICH guidelines, FDA/EMA regulations, and other international pharmaceutical quality standards.
  • Experience supporting supplier audits, quality agreements, and handling supplier-related CAPAs.
  • Excellent problem-solving skills and the ability to manage complex investigations and root cause analyses.
  • Strong written and verbal communication skills, with the ability to clearly present audit findings and quality issues to cross-functional teams.
  • Certification in quality assurance or auditing (such as ASQ, CQA, or similar) is a plus.
  • Ability to travel domestically and internationally (up to 10%).
Responsibilities
  • Support the supplier qualification process, including risk assessments, review of technical documentation, and evaluation of suppliers' capabilities.
  • Maintain quality agreements with key suppliers to define quality expectations and responsibilities.
  • Track supplier key performance indicators (KPIs), conduct periodic reviews of supplier performance, and provide feedback to drive continuous improvement.
  • Oversee and assess the impact of changes in supplier processes, materials, and components on product quality. Ensure timely communication and collaboration with internal stakeholders.
  • Maintain accurate and thorough documentation of supplier quality activities, including audit reports, inspection results, and supplier performance metrics.
  • Ensure all supplier-related activities comply with global regulatory requirements, including FDA, EMA, ICH guidelines, and other applicable regulations.
  • Work closely with procurement, manufacturing, R&D, and regulatory affairs teams to address supplier-related quality issues and support product development and commercialization.
  • Support supplier quality management processes by identifying gaps, recommending solutions, and implementing best practices.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to protect vulnerable populations from serious bacterial infections.

Company Stage

IPO

Total Funding

$2.3B

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

27%

1 year growth

65%

2 year growth

131%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?